Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.

@article{Banerjee2013StudyOT,
  title={Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.},
  author={Sube Banerjee and Jennifer M Hellier and Renee Romeo and Michael W Dewey and Martin Knapp and Clive G Ballard and Robert VV. Baldwin and Peter Bentham and Chris Fox and Clive Holmes and Cornelius L. E. Katona and Claire Lawton and James E. B. Lindesay and Gill Livingston and Niall McCrae and Esme Moniz-Cook and Joanna Murray and Shirley Nurock and Martin Orrell and John O'brien and Michaela Poppe and Anna Thomas and Rebecca E. A. Walwyn and Kate Wilson and Alistair Burns},
  journal={Health technology assessment},
  year={2013},
  volume={17 7},
  pages={1-166}
}
OBJECTIVE Depression is common in dementia, causing considerable distress and other negative impacts. Treating it is a clinical priority, but the evidence base is sparse and equivocal. This trial aimed to determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 weeks post randomisation compared with placebo. DESIGN Multicentre, parallel-group, double-blind placebo-controlled randomised controlled trial of the clinical effectiveness of sertraline and mirtazapine… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…